文献标引:王坚.Graves眼病免疫治疗的新靶点[J/CD].中华临床医师杂志：电子版,2010,4(1):1-3.

参考文献:
[1]　Garrity JA，Bahn RS. Pathogenesis of graves ophthalmopathy：implications for prediction，prevention，and treatment. Am J Ophthalmol，2006，142（1）：147－153.[PubMed]
[2]　Valyasevi RW，Harteneck DA，Dutton CM，et al. Stimulation of adipogenesis，peroxisome proliferator-activated receptor-gamma（PPARgamma），and thyrotropin receptor by PPARgamma agonist in human orbital preadipocyte fibroblasts. J Clin Endocrinol Metab，2002，87（5）：2352－2358.[PubMed]
[3]　Zhang L，Baker G，Janus D，et al. Biological effects of thyrotropin receptor activation on human orbital preadipocytes. Invest Ophthalmol Vis Sci，2006，47（12）：5197－5203.[PubMed]
[4]　Kumar S，Coenen MJ，Scherer PE，et al. Evidence for enhanced adipogenesis in the orbits of patients with Graves′ ophthalmopathy. J Clin Endocrinol Metab，2004，89（2）：930－935.[PubMed]
[5]　Pritchard J，Han R，Horst N，et al. Immunoglobulin activation of T cell chemoattractant expression in fibroblasts from patients with Graves′ disease is mediated through the insulin-like growth factor I receptor pathway. J Immunol，2003，170（12）：6348－6354.[PubMed]
[6]　Kremer JM，Westhovens R，Leon M，et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med，2003，349（20）：1907－1915.[PubMed]
[7]　El Fassi D，Nielsen CH，Bonnema SJ，et al. B lymphocyte depletion with the monoclonal antibody rituximab in Graves′ disease：a controlled pilot study. J Clin Endocrinol Metab，2007，92（5）：1769－1772.[PubMed]
[8]　Bonara P，Vannucchi G，Campi I，et al. Rituximab induces distinct intraorbital and intrathyroidal effects in one patient satisfactorily treated for Graves′ ophthalmopathy. Clin Rev Allergy Immunol，2008，34（1）：118－123.[PubMed]
[9]　Wiersinga WM. Management of Graves′ ophthalmopathy. Nat Clin Pract Endocrinol Metab，2007，3（5）：396－404.[PubMed]
[10]　Paridaens D，Van den Bosch WA，Van der Loos TL，et al. The effect of etanercept on Graves′ ophthalmopathy：a pilot study.Eye，2005，19（12）：1286－1289.[PubMed]
[11]　Finamor FE，Martins JR，Nakanami D，et al. Pentoxifylline（PTX）-an alternative treatment in Graves′ ophthalmopathy（inactive phase）：assessment by a disease specific quality of life questionnaire and by exophthalmometry in a prospective randomized trial. Eur J Ophthalmol，2004，14（4）：277－283.[PubMed]
[12]　Pritchard J，Horst N，Cruikshank W，et al. Igs from patients with Graves disease induce the expression of T cell chemoattractants in their fibroblasts. J Immunol，2002，168（2）：942－950.[PubMed]
[13]　Aguirre-Balsalobre F，Mengual-Verdú E，Muñoz-Acosta JM，et al. Octreotide scintigraphy in thyroid orbi-topathy gammagrafia con ocireotido en la orbitopatia distiroidea（in English）. Arch Soc Esp Oftalmol，2007，82（3）：133－139.[PubMed]
[14]　Dorkhan M，Lantz M，Frid A，et al. Treatment with a thiazolidinedione increases eye protrusion in a subgroup of patients with type 2 diabetes. Clin Endocrinol（Oxf），2006，65（1）：35－39.[PubMed]
[15]　Lee S，Tsirbas A，Goldberg RA，et al. Thiazolidinediones induced thyroid associated orbitopathy. BMC Ophthalmol，2007，7：8.[PubMed]
[16]　Starkey K，Heufelder A，Baker G，et al. Peroxisome proliferator-activated receptor-gamma in thyroid eye disease：contraindication for thiazolidinedione use？J Clin Endocrinol Metab，2003，88（1）：55－59.[PubMed]
[17]　Vondrichova T，de Capretz A，Parikh H，et al. COX-2 and SCD，markers of inflammation and adipogenesis，are related to disease activity in Graves′ ophthalmopathy. Thyroid，2007，17（6）：511－517.[PubMed]
[18]　Stamato FJ，Maciel RM，Manso PG，et al. Colchicine in the treatment of the inflammatory phase of Graves′ ophthalmopathy：a prospective and randomized trial with prednisone. Arq Bras Oftalmol，2006，69（6）：811－816.[PubMed]